ContraVir Pharmaceuticals Inc.
News
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Globe Newswire KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ( Pharma Two B ), a late-clinical stage company that is developing P2B001, an innovative combination...\n more…
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nHepion Pharmaceuticals just reported results for the second quarter of 2024.\nThe post HEPA Stock Earnings: Hepion Pharmaceuticals...\n more…
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Benzinga Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson's disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans to list on Nasdaq under "PHTB".\n more…
Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring
TipRanks Financial Blog An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. and Pearl Merger Su...\n more…
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Globe Newswire Pharma Two B Ltd. ( Pharma Two B ) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. ( Hepion ) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...\n more…
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Increase in Short Interest
Ticker Report Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA - Get Free Report) saw a large increase in short interest in June. As of June 30th, there was short interest totalling 24,400 shares, an increase of 58.4...\n more…